Poor Study Results Sink Corcept

Shares of Corcept Therapeutics ( CORT) plummeted Friday after the company said a late-stage clinical trial intended to prove the effectiveness of its treatment for psychotic major depression missed its goal.

In one of three phase III trials, the drug, Corlux, failed to improve a target number of patients' scores on a psychiatric-symptoms rating scale by 50%, the study's main target.

Shares slumped 44 cents, or 34%, to 87 cents on trading volume that was much heavier than normal.

"The study revealed no meaningful separation in response between patients receiving Corlux and patients receiving placebo," the company said in a press release. Results from a previous trial showed an unusually high patient response to a placebo, added Corcept's president and head of development Dr. Robert Roe.

At day 56 of the trial, for example, 95% of patients given the drug, and 95% of patients taking a placebo showed at least a 50% response measured by a specific type of psychiatric-rating scale.

Corcept said the results of two of the study's secondary goals were also poor. Despite the findings, Corcept will continue to enroll patients in another phase III study of the drug. Phase III is the stage of trials conducted to support Food and Drug Administration approval.

More from Stocks

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

GE's $11.1 Billion Deal With Wabtec Should Have Warren Buffett Feeling Very Sad

GE's $11.1 Billion Deal With Wabtec Should Have Warren Buffett Feeling Very Sad

How to Trade Apple Ahead of Alphabet's Launch of YouTube Music

How to Trade Apple Ahead of Alphabet's Launch of YouTube Music

18 Top Stocks Hedge Funds Own That Goldman Sachs Thinks Will Keep Outperforming

18 Top Stocks Hedge Funds Own That Goldman Sachs Thinks Will Keep Outperforming